Syquant Capital SAS’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Syquant Capital SAS’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,500	Closed	-$339K	–	44
2022 Q2	$339K	Buy	+4,500	New	+$200K	0.38%	21
2021 Q1	–	Sell	-5,000	Closed	-$609K	–	85
2020 Q4	$609K	Buy	+5,000	New	+$548K	0.16%	66

Syquant Capital SAS's TPTX Position: Q3 2022 in Review

Syquant Capital SAS sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 4,500 shares — an estimated $339K sold.

Syquant Capital SAS first reported a position in TPTX in Q4 2020 and held it in 2 quarters. The position peaked at $609K in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Syquant Capital SAS reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Syquant Capital SAS sold 4,500 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $339K.
Syquant Capital SAS first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
Syquant Capital SAS's Turning Point Therapeutics, Inc. Common Stock position peaked at $609K in Q4 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Syquant Capital SAS's 13F filing for Q3 2022, filed 11 Oct 2022.